Evelyn Baker Latest Blog Posts

Aiming for the Photography Crown ON1 isn't just tinkering on the fringes with their new Photo RAW 2027 release—they're diving headfirst into the deep end, aiming to outdo giants in the RAW processing world. I've seen my share of software updates that don't move the needle, but this one's packed to the gills with updates that photographers have been clamoring for. What's...

Scandium-Aluminum Alloy: A Game Changer? A joint venture announcement has investors buzzing, as Cymat Technologies Ltd. is gearing up for a game-changing push into the scandium-aluminum (Sc-Al) alloy space. Now, don't shrug this off as another run-of-the-mill alliance—there's meat on these bones, and it's worth a close look. The key takeaway is that Cymat's venture with...

Gamehaus Moves Deep Into AI Waters Sailing right into a new frontier, Gamehaus is all set to splash $19.6 million for a hefty slice of Techforge, the parent of the AI-powered Anamana. Gamehaus: a game publisher taking aim at becoming an AI content giant. You might ask yourself, "Can they pull it off?" Well, that's what I'm pondering over my lukewarm coffee today....

Pivotal Leadership Change at Carnegie Mellon's SEI Big moves are coming out of Pittsburgh, folks. Carnegie Mellon University just shook things up by naming Jason M. Brown as the next director and CEO of their Software Engineering Institute (SEI). This signal-fire moment catches my eye as the SEI stands at the cutting edge of software, artificial intelligence, and...

Unveiling America's Drone Manufacturing Surge Straight talk, folks—there's a roaring play on the horizon with drones, and Neros is right at the spearhead. A fresh $450 million conditional loan from the Office of Strategic Capital (OSC) is lighting up the field, and if you're not paying attention, you're already falling behind. Add $165 million more in cold hard Neros...

Lupin's Big Break Let's cut right to the chase: Lupin's latest FDA approval is no small potatoes. It's like getting a golden ticket in the pharma world, especially when you've been in the trenches as long as they have. As the first-to-file for their Amifampridine Tablets, 10 mg, this Indian giant is snagging that sweet 180-day exclusivity window. And in the cutthroat...

If you thought anniversaries were just about looking back, think again! In Wujiang, November 1st was all about forging ahead. Scholars and local officials weren't just reminiscing about Fei Xiaotong's landmark field study at Jiangcun 90 years ago; they were strategizing how to apply the sociologist's insights to today's economic and community challenges. Marking a Legacy...

LG's Strategic Battery Play You know it's serious when a company pushes into new territories with gusto. LG Energy Solution isn’t tiptoeing with their recent financials—Q3 2026 showed 'em raking in KRW 9.6 trillion in revenue. That's a mighty 27.6% uptick from the previous quarter, no small potatoes by any stretch, especially when their operating profit stands solid...

Diving Into Renters Insurance: What You Need to Know Renters insurance isn't just another unnecessary add-on; it's practically a necessity if you're renting. Joseph Puckett, of Golseth and Puckett Agency: Allstate Insurance, gives us the lowdown on the essential protection renters need but often overlook. The Myth and the Reality Ah, the age-old misconception—many...

Hexagon's Bold Move into Non-Destructive Testing Hexagon's latest play is turning heads in the measurement technology market. They've just wrapped up a strategic acquisition, snagging none other than Waygate Technologies from Baker Hughes. For those not familiar, Waygate's no small fry—this outfit's got a century-plus history in non-destructive testing (NDT) services....

Key Information for ATYR Pharma Shareholders ATYR Pharma, Inc. has recently faced significant challenges that have caught the attention of its shareholders. Investors who have purchased shares of ATYR during the specified class period are encouraged to stay informed about the ongoing legal developments. Engaging with The Gross Law Firm can provide shareholders with the...

Zymeworks Keeps Stock Rating Steady After ESMO 2024 Results Zymeworks Inc. (NASDAQ: ZYME) has maintained its stock rating and price target after revealing encouraging results from its recent cancer treatment clinical trials at a significant medical conference. The ratings firm H.C. Wainwright has reiterated a Neutral rating and set a price target of $10.00 per share...

Introduction to the New ETF A recently introduced exchange-traded fund (ETF), known as the REX Bitcoin Corporate Treasury Convertible Bond ETF (BMAX), is gaining attention for its focus on convertible bonds from companies that have Bitcoin included in their financial strategies. This ETF began trading recently and represents a growing trend in the investment landscape....

iBio's Strategic Investment Announcement iBio, Inc. (NYSE: IBIO), a pioneer in AI-driven antibody immunotherapies, has made an impactful stride in its mission, announcing the successful closure of a private investment offering totaling over $650,000 from its Board of Directors and corporate officers. This investment is a significant vote of confidence in iBio's strategy...

Simulmedia Appoints Jonathan Steuer as Chief Scientist Simulmedia, a leader in cross-channel TV and connected TV (CTV) advertising, is thrilled to announce a significant addition to its executive team. Jonathan Steuer, a prominent figure in media research and data science, has been appointed as the Chief Scientist. With a remarkable background as a scientist and...